Cytokinetics Inc (NASDAQ: CYTK) is -7.63% lower on its value in year-to-date trading and has touched a low of $40.53 and a high of $75.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $43.28 in the last trading session, with the day’s gains setting it 0.17%.
Currently trading at $43.45, the stock is -4.06% and -5.93% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.16 million and changing 0.39% at the moment leaves the stock -16.04% off its SMA200. CYTK registered -33.35% loss for a year compared to 6-month loss of -23.44%. The firm has a 50-day simple moving average (SMA 50) of $46.1894 and a 200-day simple moving average (SMA200) of $51.74945.
The stock witnessed a -4.27% gain in the last 1 month and extending the period to 3 months gives it a -10.69%, and is -1.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.74% over the week and 5.37% over the month.
Cytokinetics Inc (CYTK) has around 498 employees, a market worth around $5.14B and $18.47M in sales. Profit margin for the company is -3191.11%. Distance from 52-week low is 7.20% and -42.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-94.66%).
The EPS is expected to shrink by -8.67% this year
478.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 115.22% of the company’s shares. The shares outstanding are 118.21M, and float is at 115.45M with Short Float at 12.19%. Institutions hold 114.71% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $$794.97 million. The investor’s holdings represent 14.3958 of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $$624.32 million to account for 11.3056 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 11.2218 and valued at over $$619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $$440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham, the company’s EVP Research & Development. SEC filings show that Malik Fady Ibraham sold 2,000 shares of the company’s common stock on Mar 18 ’25 at a price of $43.58 per share for a total of $87160.0. Following the sale, the insider now owns 0.14 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on Mar 17 ’25 that Callos Andrew (EVP, Chief Commercial Officer) sold a total of 2,775 shares of the company’s common stock. The trade occurred on Mar 17 ’25 and was made at $44.38 per share for $0.12 million. Following the transaction, the insider now directly holds 34888.0 shares of the CYTK stock.
Still, SEC filings show that on Mar 17 ’25, Malik Fady Ibraham (EVP Research & Development) disposed off 4,389 shares at an average price of $44.38 for $0.19 million. The insider now directly holds 101,005 shares of Cytokinetics Inc (CYTK).
